Navigation Links
Microchip Biotechnologies, Inc. Enters Into License Arrangement With GE Healthcare for Fundamental Microfluidic Patents

DUBLIN, Calif., April 22 /PRNewswire/ -- Microchip Biotechnologies, Inc. (MBI) announces that it has entered into a multi-patent license agreement with GE Healthcare that significantly enhances MBI's intellectual property portfolio supporting the development of lab-on-a-chip devices. The patents cover design and methods for creating integrated fluidic microchip devices.

"Licensing these fundamental patents continues to build our strong intellectual property position in microfluidic devices," said Dr. Stevan Jovanovich, President and CEO of MBI. "Microfluidic devices will play a critical role in next-generation instrumentation that delivers fully-automated, cost-effective bioassay solutions in the life sciences, applied sciences, and molecular diagnostics."

California-based MBI will use the technology licensed from GE Healthcare to develop and commercialize easy to use Sample-To-Answer systems using advanced microfluidic technologies. Microfluidics deals with the behavior, precise control, and manipulation of microliter and nanoliter volumes of fluids to perform life science assays. Microfluidics technologies are essential for development of lab-on-a-chip devices for DNA analysis and molecular diagnostics. Microfluidic devices are smaller, faster and cheaper than the laboratory benchtop instruments that they are designed to replace, and are exquisitely suited for clinical and forensic systems used at the bedside or in the field.

About Microchip Biotechnologies

Microchip Biotechnologies, Inc. is an early-stage privately-held company located in Dublin, California that is developing advanced nanofluidic sample preparation and analytical instrumentation for Life Sciences, Applied Sciences, and Diagnostics markets. These solutions are based on MBI's proprietary "NanoBioProcessor(TM) platform and associated "Microscale-on-Chip-Valves" (MOV(TM)). More details can be found on the Company's website:

SOURCE Microchip Biotechnologies, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. Canadian Centre for DNA Barcoding to Participate in Microchip Biotechnologies Early Access Program for Microchip-Based DNA Sample Preparation and Cycle Sequencing
2. Microchip Biotechnologies, Inc. Collaborating With Stanford University on Developing a Front End Microfluidic-Based Sample Preparation System for Pyrosequencing Platforms
3. Team develops energy-efficient microchip
4. Quick microchip test for dangerous antibiotic resistant bacteria
5. Microchip Biotechnologies, Inc. Secures Exclusive License to Use New University of Alberta Technology for Developing Microfluidic Devices
6. Millennium Biotechnologies, Inc. Signs Marketing and Distribution Agreement with Ferring Pharmaceuticals
7. Raven biotechnologies, inc. and Wyeth Pharmaceuticals Extend Evaluation Period of Selected Raven Antibodies
8. Millennium Biotechnologies, Inc. Launches SURGEX(TM) the First Scientifically Validated Sports Nutritional Product Created from the Medical Markets
9. Maven Biotechnologies, LLC to Present at BIOCOM Investor Conference
10. Alta Bates Summit Medical Center Opens Two Warm, Supportive Patient Centers: Carol Ann Read Breast Health Center and Family Resource Center
11. CyberKnife Radiosurgery Used to Treat Lung Tumors at 90 Percent of Centers Worldwide
Post Your Comments:
(Date:6/27/2016)... NC (PRWEB) , ... June 27, 2016 , ... ... mission to bring innovative medical technologies, services and solutions to the healthcare market. ... and implementation of various distribution, manufacturing, sales and marketing strategies that are necessary ...
(Date:6/24/2016)... SAN DIEGO , June 24, 2016 /PRNewswire/ ... that more sensitively detects cancers susceptible to PARP ... individual circulating tumor cells (CTCs). The new test ... of HRD-targeted therapeutics in multiple cancer types. ... therapies targeting DNA damage response pathways, including PARP, ...
(Date:6/23/2016)... , June 23, 2016   Boston ... of novel compounds designed to target cancer stemness ... has been granted Orphan Drug Designation from the ... treatment of gastric cancer, including gastroesophageal junction (GEJ) ... inhibitor designed to inhibit cancer stemness pathways by ...
(Date:6/23/2016)... SANTA MONICA, Calif. , June 23, 2016  The Prostate Cancer ... to pioneer increasingly precise treatments and faster cures for prostate cancer. Members of ... 77 institutions across 15 countries. Read More About the ... ... ...
Breaking Biology Technology:
(Date:5/12/2016)... 2016 , a brand of ... results from the Q1 wave of its quarterly wearables ... consumers, receptivity to a program where they would receive ... insurance company. "We were surprised to see ... Michael LaColla , CEO of Troubadour Research, "primarily because ...
(Date:4/28/2016)... 2016 First quarter 2016:   ... with the first quarter of 2015 The gross margin ... (loss: 18.8) and the operating margin was 40% (-13) ... Cash flow from operations was SEK 249.9 M (21.2) , ... unchanged, SEK 7,000-8,500 M. The operating margin for 2016 ...
(Date:4/15/2016)... , April 15, 2016  A new ... make more accurate underwriting decisions in a fraction ... timely, competitively priced and high-value life insurance policies ... screenings. With Force Diagnostics, rapid testing ... lifestyle data readings (blood pressure, weight, pulse, BMI, ...
Breaking Biology News(10 mins):